<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 20-year-old male with <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> complicated by <z:chebi fb="0" ids="6775">mesalazine</z:chebi>-associated severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> is described </plain></SENT>
<SENT sid="1" pm="."><plain>The patient developed <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> four months after the start of <z:chebi fb="0" ids="6775">mesalazine</z:chebi> therapy </plain></SENT>
<SENT sid="2" pm="."><plain>He was treated with antithymocyte globulin, <z:chebi fb="0" ids="4031">cyclosporine</z:chebi>, and granulocyte colony-stimulating factor (G-CSF) and responded well </plain></SENT>
<SENT sid="3" pm="."><plain>Hematological complications of <z:chebi fb="0" ids="6775">mesalazine</z:chebi> are rare, but if bone marrow suppression is detected, immediate cessation of the drug and intensive immunosuppressive treatment with G-CSF should be considered </plain></SENT>
</text></document>